Healthcare major Gilead Sciences, Inc. (GILD) was much discussed during the pandemic as it developed the first antiviral drug approved to treat COVID-19. As COVID-19 cases have fallen drastically, GILD’s Veklury’s (Remdisivir) sales declined 51.9% year-over-year to $925 million in the last quarter.
However, GILD’s revenue and EPS in the last quarter were higher than analyst estimates. Its EPS came 32.9% higher than the consensus estimate, while its revenue beat analyst estimates by 14.8%.
